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ABSTRACT
Topoisomerases are ubiquitous proteins found in
all three domains of life. They change the topology
of DNA via transient breaks on either one or two
of the DNA strands to allow passage of another
single or double DNA strand through the break.
Topoisomerases are classified into two types:
type I enzymes cleave one DNA strand and pass
either one or two DNA strands through the break
before resealing it, while type II molecules cleave
both DNA strands in concert and pass another
double strand through the break followed by religa-
tion of the double strand break. Here we review
recent work on the structure of type I enzymes.
These structural studies are providing atomic
details that, together with the existing wealth of bio-
chemical and biophysical data, are bringing our
understanding of the mechanism of action of these
enzymes to the atomic level.
INTRODUCTION
Topoisomerases are ubiquitous proteins found in all three
domains of life (bacteria, archaea and eukarya). They are
capable of changing the topology of DNA via transient
breaks on one or two of the DNA strands to allow passage
of either a single or double DNA strand through the
break. Topoisomerases have been involved in several cel-
lular processes, such as transcription, replication and
recombination, and the importance of their cellular role
is underscored by the fact that they are the target of sev-
eral cancer chemotherapeutic agents and antibiotics [for a
review, see (1)]. Topoisomerases are classiﬁed into two
types: type I enzymes cleave one DNA strand and pass
either one or two strands through the break before reseal-
ing it, while type II molecules cleave both DNA strands in
concert and pass another double strand through the
break followed by religation of the double strand break.
Type I enzymes do not require any high-energy cofactor
for activity; the reaction is driven by the energy stored in
the supercoiled DNA as torsional strain. Type II enzymes
also do not require an external source of energy for the
cleavage/religation part of the reaction, but they do utilize
ATP hydrolysis to drive conformational changes in the
protein during the reaction cycle.
Type I enzymes have been further classiﬁed into three
diﬀerent families: types IA, IB and IC (2). Family mem-
bers are similar to each other in sequence, structure and
atomic mechanism. However, members of one family
show no sequence or structural similarities to members
of the other families. The atomic mechanisms employed
for cleavage and religation of the DNA by diﬀerent
families have only superﬁcial similarities. Type I enzymes
operate by forming a transient phosphotyrosine covalent
bond with one end of the broken DNA strand, either the
50 or the 30 end, followed by passage of the unbroken
strand through the break, and ultimately resealing of the
break. In this context, only two possible mechanisms of
relaxation are possible: enzyme-bridged strand passage,
where the protein mediates the opening of one strand to
allow passage of the other, and swiveling, which involves
the rotation of the DNA strands. One important diﬀer-
ence between these mechanisms is the need to hold one or
both ends of the broken DNA strand. During enzyme-
bridged strand passage, it is necessary to non-covalently
hold one end of the broken strand while the other end is
covalently attached to the active site tyrosine. On the
other hand, the swiveling mechanism requires the non-
covalently bound end of the DNA to move around
freely and is not attached to the protein. It is clear that
each family of type I enzymes has to employ one of the
two relaxation mechanisms and form either a 50 or 30
covalent intermediate. It is now established that type IA
enzymes form transient 50 covalent intermediates and relax
DNA through an enzyme-bridged strand-passage mechan-
ism, while type IB and IC enzymes both form 30 covalent
intermediates and relax DNA by swiveling, although the
details of how this is accomplished are probably very
diﬀerent.
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without the need of an external source of energy, such
as ATP hydrolysis. So far, the only exception is reverse
gyrase, which introduces positive supercoils with the aid of
ATP hydrolysis, although the way the strand passage and
ATP hydrolysis steps are coupled is still not clear. To relax
DNA, type I enzymes garner the energy stored as torsional
stress in the supercoiled DNA. The way the stored energy
in the DNA is transformed into changes in the protein as
the reaction proceeds is still not understood and remains
one of the major future challenges in understanding not
only type I topoisomerases, but all topoisomerases.
TYPE IA TOPOISOMERASES
Type IA enzymes have been found in bacteria, archaea
and eukarya and there are clear sequence similarities
among all members, suggesting a strong structural and
mechanistic conservation (3). They form a phosphotyro-
sine linkage to the 50 end of the broken DNA strand while
non-covalently holding the free 30-end hydroxyl group.
Relaxation activity occurs in the absence of a high-
energy cofactor, but in the presence of divalent cations.
The exact role of these cations has not been fully deter-
mined, however they are needed for DNA relaxation (4).
Although they are an attractive target for chemotherapeu-
tic agents, there are no known inhibitors or drugs that
target type IA enzymes. Type IA topoisomerases relax
only negatively supercoiled DNA and require single-
stranded DNA regions for activity (5). The requirement
of single-stranded DNA for activity provides a plausible
mechanism for sensing the overall topological state of
DNA as single-stranded regions are only found in nega-
tively supercoiled or underwound DNA but not in posi-
tively supercoiled or overwound DNA. Thus, the presence
of single-stranded regions, a property of DNA that can be
monitored locally, could serve as an indicator of the global
topological state of DNA.
The core structure of type IA topoisomerases, typically
of around 67kDa in molecular weight, has a characteristic
toroidal fold formed by four domains. The toroidal fold
was ﬁrst observed in Escherichia coli topoisomerase I (6)
and later in E. coli topoisomerase III (7), Thermotoga
maritima topoisomerase I (8), and reverse gyrase from
Archaeoglobus fulgidus, a hyperthermophilic archaeal
organism (9) (Figure 1). Reverse gyrase is unique as it
consists of a topoisomerase domain fused to a helicase
domain at the N-terminus of the protein. The core
domain is followed by a C-terminal domain of variable
size. Sequence comparison of the C-terminal region
extending from the core domain of the type IA enzymes
shows that this region does not present the same level of
conservation as the core. The C-terminal domains can
vary greatly in size and play a role in DNA/protein inter-
actions (10–12). In the case of E. coli topoisomerase III,
deletion of this C-terminal domain is deleterious, although
its removal does not abolish activity completely (13).
In the case of E. coli topoisomerase I, the C-terminal
domain is essential for activity (14,15). In both cases, the
C-terminal domain is responsible for single-stranded
DNA binding and confers higher DNA binding aﬃnity
(10,12,13). The structures of the C-terminal domain of
E. coli topoisomerase I (16) and the intact T. maritima
topoisomerase I (8) reveal the presence of zinc-ribbon
single-stranded DNA binding motif. The structure of the
T. maritima topoisomerase I shows the way the core
domain and the C-terminal domain are arranged relative
to each other, but the structural bases for the role of this
domain in the overall reaction are still unknown.
A combination of biochemical, biophysical and struc-
tural studies has helped reveal the atomic mechanism of
the type IA enzymes. A detailed model on how type IA
enzymes perform complex topological rearrangements was
proposed several years ago based on the structure of
E. coli topoisomerase I (6). Subsequent biochemical
Figure 1. Structure of a type IA topoisomerase. E. coli topoisomerase
III is shown to illustrate the overall structure of a type IA topoisome-
rase and the typical toroidal fold observed in all members of this type.
(A) Diagram showing the structure of the apo-enzyme [PDB 1D6M
(7)]. In the absence of DNA, the active site, found at the intersection
of domains I and III (encircled), is buried. (B) Diagram showing the
structure of a complex with single-stranded DNA [PDB 1I7D (23)].
Note the movement of domains that occurs in order to accommodate
DNA. In both diagrams, the four major domains of the protein are
colored red, blue, purple and green for domains I, II, III and IV,
respectively. The single-stranded DNA binding groove, shown circled
in black, extends from domain IV to the active site. The active site
residues as well as the single-stranded DNA in the complex are shown
in a ball and stick representation.
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disulﬁde bridge trapped some of the proposed intermedi-
ates and conﬁrmed the general features of the mechanism
of action (17), in particular that the enzyme opens up
through a large conformational change and sequesters
the passing DNA strand inside the protein. Recent single
molecule experiments (18,19) have further conﬁrmed the
general features of the proposed mechanism. These experi-
ments, in conjunction with the wealth of existing biochem-
ical data, conﬁrmed that the enzymes change the linking
number in steps of one, as is mandated in an enzyme-
bridged strand-passage mechanism.
The proposed mechanism of action involves several
steps (Figure 2), and crystal structures for some of these
intermediate steps have been obtained (20–22). The struc-
tures revealed that the enzyme and the DNA have to
change conformation during the catalytic cycle in a coor-
dinated manner. Structures of the apo-state of E. coli
topoisomerase I and III (6,7), T. maritima topoisomerase
I (8) and A. fulgidus reverse gyrase (9) showed the enzymes
in a closed conformation with the active site not fully
formed. The structure of E. coli topoisomerase III in com-
plex with a short oligonucleotide shows that type IA
enzymes have to undergo conformational changes to
form the active site and that these changes are not only
conﬁned to the relative movement of the domains, but also
involve small but important rearrangements in some of the
domains of the molecule (20,23), in particular domain IV,
which is directly involved in forming a single-stranded
DNA binding groove. Additionally, the structure of a
fragment of E. coli topoisomerase I (21) indicated that
the enzyme can undergo dramatic rearrangements of one
of its domains (domain II), while, the structure of E. coli
topoisomerase I in complex with a short oligonucleotide
(22) shows the structure of an intermediate where the
active site is not yet fully formed, but some movements
of secondary structure elements in domain IV have started
to occur. There is still no structure of a covalent interme-
diate that shows the crucial interactions with the 50 and 30
ends of the DNA, but recent studies of wild-type E. coli
topoisomerase III in complex with DNA showed for the
ﬁrst time a wild-type enzyme in complex with DNA per-
fectly poised for DNA cleavage (20) (Figure 3). This struc-
ture conﬁrms that the formation of a competent active site
depends on several rearrangements of the enzyme.
An initial identiﬁcation of the residues comprising the
active site was based on the structure of the apo-enzyme
(6) and sequence conservation (24). The structure of an
E. coli topoisomerase III-single-stranded DNA complex
(23) showed that a conformational change occurs upon
single-stranded DNA binding and this leads to the cre-
ation of a competent active site by bringing together resi-
dues that are distant in the apo-enzyme. In the complex
structure, the active site tyrosine, an arginine, a lysine and
a glutamate form direct contacts to the DNA near the
scissile bond. In addition, a second layer of highly con-
served amino acids surrounds the active site, including
three highly conserved acidic residues that have been
shown to be involved in magnesium binding (25). Due
to the conformational changes that occur upon binding
DNA (Figure 3), some of the residues that in the apo-
structure were observed to be distant from the putative
active site, they were found to be central to the mechanism
in the complex structure. An example is Glu7 in topo-
isomerase III, which is completely conserved and interacts
directly with DNA, but is located several Angstroms away
from the active site in the apo-structure and whose exact
role could not be surmised from biochemical studies.
Several biochemical studies, mostly using site-directed
mutagenesis [for example (26–32)] have conﬁrmed the
role of many of the residues identiﬁed by these structures.
Due to their dynamic nature, type IA topoisomerases are a
very good example of proteins where understanding the
catalytic mechanism in the absence of structures is almost
impossible.
There are still many open questions regarding the
atomic mechanism of type IA topoisomerases. The chem-
istry of the mechanism of cleavage and religation, the
manner in which the free 30-end interacts with the protein
during the reaction, the role of magnesium, and the atomic
mechanism of strand passage are some of the questions
that remain to be answered. Our understanding of type IA
enzymes will be incomplete until we elucidate the atomic
details of the movement of one strand past the other and
how the torsional strain in DNA directs conformational
changes in the protein. Additional structural information
on the intermediate steps in the reaction cycle, especially
those with large conformational changes both in the pro-
tein and the DNA, is essential to address these diﬃcult
questions.
TYPE IB TOPOISOMERASES
Type IB enzymes have been identiﬁed in eukaryotes, pox-
viruses and bacteria, but not in archaea. Eukaryotic type
IB molecules are large, typically over 90kDa in molecular
weight, while viral and bacterial type IB molecules are
Figure 2. Diagram showing the proposed mechanism of DNA relax-
ation by type IA topoisomerases. The mechanism involves several tran-
sient conformational intermediates both of the protein and the DNA.
The sequence of the steps and the intermediates are hypothetical and
more states are likely to be involved in the cycle. Processivity by the
enzyme requires that after one relaxation event the protein continues to
another relaxation cycle without releasing the DNA. In the diagram,
the protein is shown in grey and the DNA in red/blue. The orange dot
represents the presence of the covalent protein/DNA complex. The
single-stranded DNA binding groove is shown in red or yellow.
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in size, all type IB molecules share a common fold around
the active site region and a common catalytic mechanism
(3,33,34) (Figure 4). Interestingly, these similarities extend
to the tyrosine recombinase family suggesting a common
ancestor for both type IB topoisomerases and tyrosine
recombinases (33). Type IB enzymes form a transient 30
phosphotyrosine covalent linkage with the broken end of
the DNA. They can relax both negatively and positively
supercoiled DNA without requiring divalent ions or ATP.
By breaking transiently one DNA strand, type IB enzymes
allow torsionally strained DNA to relax. As long as there
is torsional strain to drive the swiveling, the reaction will
proceed until the DNA is fully relaxed. Because of this,
type IB enzymes do not have to sense directly the global
topological state of DNA, they simply provide the means
to relieve torsional strain if some is present, even if it is
only in a local supercoiled domain.
All type IB topoisomerases have many structural and
functional characteristics in common. They all contain a
highly conserved pentad of residues forming the active
site (Tyr, Arg, Arg, Lys and His/Asn) with an identical
architecture around the active site region (Figure 5).
Eukaryotic and viral enzymes have a histidine in the
pentad, while in bacterial type IB enzymes the histidine
is replaced by an asparagine. Experiments show that the
histidine can be replaced by an asparagine in both viral
(35) and eukaryotic (36) topoisomerases, suggesting that a
histidine or an asparagine can play the same role and that
the overall mechanism of cleavage and religation is iden-
tical in all type IB enzymes. The mechanism of cleavage by
type IB enzymes has been extensively studied and the role
of diﬀerent residues in catalysis has been characterized in
great detail (37). The sequence speciﬁcity of the poxviral
topoisomerases oﬀers an unique advantage over other
topoisomerases for biochemical studies, which has allowed
exquisitely detailed biochemical studies that elucidated the
role of DNA (38,39) and diﬀerent amino acids (37,40–42)
in the cleavage reaction.
Eukaryotic type IB topoisomerases are large proteins
that contain multiple structural components that have
no counterpart in the viral and bacterial topoisomerases.
The N-terminal region of eukaryotic topoisomerases I is
dispensable for topoisomerase activity. The central or core
domain together with a C-terminal domain can reconsti-
tute a fully functional enzyme (43). These two domains are
joined by a short linker domain formed by two long hel-
ices (43). The C-terminal domain contains the catalytic
tyrosine while all other residues in the catalytic pentad
reside in the core domain. Structures of the fully func-
tional enzyme, formed by the core and C-terminal
domains and in some instances the linker domain, in com-
plex with DNA shows a C-shaped protein clamp around
duplex DNA (34,44) (Figure 4). The two regions that close
the C-clamp consist of loops that meet in a non-covalent
interaction to envelop the target DNA. In contrast to the
eukaryotic enzymes, the poxviral and bacterial type IB
topoisomerases contain two distinct domains (45,46).
The smaller amino terminal domain is involved in inter-
actions with DNA (45,47,48), while the larger domain
contains the active site and retains full enzymatic activity
(49). The structures of both domains of vaccinia virus
topoisomerase I, the best characterized and studied viral
type IB enzyme, are known (33,45) as well as the structure
of the intact Deinococcus radiodurans topoisomerase IB
(50). The structure of variola virus topoisomerases I in
complex with DNA revealed an important point: all
type IB enzymes encircle DNA in an identical fashion,
despite their diﬀerences in size. In addition, poxviral
type IB enzymes are unique in that they have a preference
for binding to speciﬁc DNA sequences. Hence, the struc-
ture of variola virus topoisomerase I in complex with
DNA (51) helps to understand the atomic basis for the
sequence speciﬁcity.
Overall, the structure of all these type IB enzymes con-
ﬁrms that eukaryotic, viral and bacterial type IB topo-
isomerases are similar despite their dissimilarities in size.
The structural conservation is particularly striking around
the active site region. Even though the N-terminal domain
in the bacterial and viral enzymes is less conserved, there
are marked commonalities with the equivalent region in
the larger enzymes. Clearly, the smaller type IB enzymes
Figure 3. Active site of E. coli topoisomerase III, a type IA topoisomerase. The diagrams show the active site region in diﬀerent complexes. (A) Apo-
structure, where the protein is in a closed conformation and the active site is buried between domains I and III [PDB 1D6M (7)]. (B) Intermediate
structure, where the DNA starts entering the active site but it is not yet positioned properly for cleavage/religation [PDB 2O59 (20)]. (C) Fully
formed active site in the wild-type enzyme, with the single-stranded DNA positioned and the active site tyrosine poised for cleavage [PDB 2O19 (20)].
The diagrams illustrate the way the active site is assembled and the interactions with single-stranded DNA. Domain I is shown in red and domain III
in purple. Some of the side chains forming the active site are shown, as well as some possible hydrogen bonds. The single-stranded DNA is shown as
sticks.
696 Nucleic Acids Research, 2009, Vol. 37,No. 3Figure 5. Active site of type IB topoisomerases. The diagrams show the active site region in two diﬀerent type IB topoisomerases. (A) Active site in
the structure of a non-covalent complex of human topoisomerase I with DNA [PDB 1A35 (34)]. Note the presence of the amino acids forming the
catalytic pentad, Arg488, Lys532, Arg590, His632 and Tyr723 (in this structure the tyrosine was mutated to a phenylalanine). (B) Active site in
the structure of a covalent complex of variola virus topoisomerase I with DNA [PDB 2H7F (51)]. Note the equivalent pentad of amino acids in the
active site and the formation of the covalent intermediate between the tyrosine and the 30 end of the broken strand. The diagrams serve to illustrate
the high similarity between the active sites of the smaller and larger type IB enzymes and also the structures of non-covalent and covalent complexes.
Figure 4. Structures of type IB topoisomerases. Diagrams of the structures of eukaryotic and viral type IB topoisomerases. (A) Structure of human
topoisomerase I in non-covalent complex with DNA [PDB 1A35 (34)]. The protein encircles the DNA by forming a clamp around it. The protein is
composed of two domains: a core domain, shown in red and blue, and a C-terminal domain, shown in green. (B) Structure of variola virus
topoisomerase I in covalent complex with DNA [PDB 2H7F (51)]. The viral and bacterial type IB enzymes are composed of two domains: an
N-terminal domain, shown in red, and a larger, C-terminal domain, shown in blue. Note the marked similarities between the human and poxviral
proteins despite their great disparity in size. In the case of human topoisomerase I, the core and C-terminal domains are joined by a linker domain,
which is not present in this structure but that has been observed in other structures (44). The DNA in the complexes is shown in a ball and stick
representation.
Nucleic AcidsResearch, 2009, Vol.37,No. 3 697represent an abbreviated form of the larger eukaryotic
topoisomerases where all the essential regions are present.
The mechanisms of cleavage/religation and DNA relax-
ation are, without any doubt, identical.
Type IB enzymes relax DNA by a mechanism termed
‘controlled rotation’, where one DNA strand swivels
around the other. A swiveling mechanism predicts that
the enzymes relax DNA in steps of n, and this has been
conﬁrmed recently by single-molecule experiments on vac-
cinia virus, yeast and human topoisomerase IB (52,53).
The single-molecule experiments also indicate that the
swiveling is slowed down by friction created by the inter-
action between the enzyme and the DNA, consistent with
the embracing of the DNA by the protein as observed in
the structures of human and variola virus topoisomerase I
in complex with DNA (34,51).
Eukaryotic type IB topoisomerases have received addi-
tional attention as important chemotherapeutic targets.
They are the target of important anticancer compounds
such as camptothecins (54–57), indolocarbazoles (58) and
indenoisoquinolines (59–61). Although type IB enzymes
are not widespread in bacteria, they are present in some
important human pathogens, such as Pseudomonas aeur-
oginosa and Bordetella parapertussis. Hence, bacterial type
IB enzymes could serve as targets of chemotherapeutic
agents, especially now that structures are starting to
reveal the atomic diﬀerences between human, viral and
bacterial enzymes. The structures of ternary complexes
of the enzyme, DNA and drugs (62–65) reveal the drug
interactions at the atomic level and this may be helpful in
the development of better type IB poisons. Given the
importance of type IB enzymes in cancer therapeutics, it
is likely that this will continue to be a fruitful study area
and that the information garnered will also shed light on
the mechanism of action of the enzymes.
As is the case with the type IA enzymes, there are still
many details of the mechanism of type IB enzymes that
need to be elucidated. Unlike type IA enzymes, the struc-
tures of both covalent and non-covalent intermediates of
type IB enzymes are available. Together with the wealth of
biochemical information, these structures have helped us
understand the cleavage and religation mechanism in great
detail. Unfortunately, there is scant atomic information
on the way that type IB enzymes drive DNA relaxation.
The changes that occur in the protein as the DNA swivels
inside the C-clamp are yet to be elucidated. The same is
true about the conformational changes in the DNA. Even
though the single-molecule experiments suggest the pres-
ence of atomic friction due to the interaction of the pro-
tein and DNA, the details of this process are largely
unknown. Capturing intermediates in the relaxation pro-
cess is not an easy task, but they are required in order to
truly understand the atomic mechanism of action.
TYPE IC TOPOISOMERASES
The third family, type IC topoisomerases, was recently
deﬁned with the realization that topoisomerase V is dis-
tinct from all other topoisomerases. DNA topoisomerase
V was originally found in the hyperthermophile
Methanopyrus kandleri isolated from a deep-water ‘black
smoker’ chimney in the Gulf of California (66). Later on
its presence was conﬁrmed in other Methanopyrus isolates
from around the world (A. Slesarev, personal communica-
tion). In common with type IB enzymes, topoisomerase V
cleaves one DNA strand, forms a transient phosphotyro-
sine bond with the 30 end of the broken strand, can relax
positive and negative supercoils, and does not require the
presence of magnesium or ATP (67). Despite these bio-
chemical similarities, it shows no sequence or structural
similarity to other topoisomerases. Topoisomerase V is a
large enzyme, over 100kDa in molecular weight, with
unusual characteristics. Not only can it relax DNA iden-
tically to other topoisomerases (67), but it is also involved
in DNA repair (68). The two diﬀerent catalytic activities
are found in the same polypeptide: topoisomerase activ-
ity resides in the N-terminus of the protein, while the
C-terminus of the protein possesses apurinic/apyrimidinic
(AP) site-processing activity, normally associated with
base excision DNA repair (69). Sequence analysis indi-
cates that the protein contains 24 helix-hairpin-helix
(HhH) DNA binding motifs arranged in 12 tandem
(HhH)2 domains (70) that follow the topoisomerase
domain (68). N-terminal constructs as small as 30kDa
comprising the topoisomerase domain have full topo-
isomerase activity. The AP site-processing activity resides
in the C-terminal 34kDa fragment of the protein (69),
which also contains several putative HhH motifs (68).
The minimal construct with both topoisomerase and
DNA repair activities is a 78kDa N-terminal fragment
(69). Topoisomerase V catalyzes DNA relaxation under
extreme conditions. It has maximal topoisomerase activity
at around 1088C and is still active at 1228C (71). It is also
active in a wide range of conditions, up to 0.65M NaCl or
KCl and up to 3.1M potassium glutamate. These proper-
ties have been attributed to the HhH motifs, as fragments
containing fewer motifs show optimal activity in a nar-
rower set of conditions and also a marked loss of proces-
sivity (69).
The structure of a 61kDa N-terminal fragment of
topoisomerase V comprising the topoisomerase domain
and eight HhH motifs reveals a fold that is not related
to the folds observed in any other topoisomerase, tyrosine
recombinase, or other known protein (72) (Figure 6A).
The composition of the active site of topoisomerase V is
similar to the one in type IB molecules and includes the
active site tyrosine, two arginines, a lysine and a histidine
(Figure 6B). The key diﬀerence between the active site of
type IB and type IC enzymes is that the spatial arrange-
ment of these residues is diﬀerent. In addition, an acidic
residue in topoisomerase V has no equivalent in type IB
enzymes, suggesting an alternative mechanism of catalysis.
Interestingly, type IA enzymes do contain an acidic resi-
due in the active site, but it is not known whether the
acidic amino acids play a similar role in catalysis.
Furthermore, the structure suggests that a large confor-
mational change in the protein is needed for activity,
which could alter the conformation and position of the
residues in the active site, similarly to what was observed
in type IA enzymes (see above). The mechanism of DNA
cleavage and religation employed by topoisomerase V is
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that topoisomerase V employs a diﬀerent mechanism from
type IB enzymes (72) as mutation of equivalent residues in
both enzymes does not produce similar reductions in
relaxation activity. Further studies are needed to elucidate
the exact mechanism of catalysis, the residues involved,
and their role in the cleavage/religation reaction.
Topoisomerase V also has DNA repair activity, but the
structure of the domain containing the AP site processing
activity is not known yet and the residues involved in
DNA repair have not been identiﬁed.
The relaxation mechanism of this new topoisomerase is
not nearly as well understood as that of the other topo-
isomerases. Recent single-molecule experiments estab-
lished that the mechanism of action of topoisomerase V
is similar to the ‘controlled rotation’ mechanism proposed
for type IB enzymes, where relaxation occurs in steps of n
(73). Furthermore, the topoisomerase domain is active in
the absence of any of the HhH repeats, suggesting that the
topoisomerase domain may be able to relax DNA without
having to completely encircle it. These observations
strongly suggest that although type IB topoisomerases
and topoisomerase V have overall mechanistic similarities,
the way they perform the reaction may be very diﬀerent at
the atomic level.
The similarities between topoisomerases V and type IB
enzymes in the overall relaxation mechanism are striking:
both work by swiveling and form 30 covalent intermedi-
ates. Even more remarkable are the diﬀerences: no
sequence or structural similarity and a diﬀerent catalytic
mechanism for cleavage and religation. This clearly shows
that the two types of enzymes represent two diﬀerent solu-
tions to the same overall problem. This observation is even
more interesting when viewed in the context of all other
topoisomerases. There appears to be two general mechan-
isms employed by topoisomerases for DNA relaxation: (a)
type IA and type II enzymes employ an enzyme-bridged
strand-passage mechanism, with biochemical similarities
in the way they cleave/religate DNA, and structural simi-
larities in various domains, such as the toprim domain (3),
(b) type IB enzymes all share a common fold and employ
the same swiveling mechanism for DNA relaxation.
Topoisomerase V illustrates a completely diﬀerent solu-
tion to the same topological problem without any struc-
tural, sequence or biochemical similarity to either type IB
or type IA/type II enzymes.
CONCLUSIONS
Over the last few years, the elucidation of the structures of
various members of all the topoisomerase types has helped
to bring our understanding of the mechanism of action of
these important enzymes to the atomic level. In the case
of type I enzymes, structures of the apoenzymes, along
with enzyme–DNA complexes have provided exquisitely
detailed snapshots of the enzymes during their catalytic
cycle. The structures of type IA enzymes in diﬀerent
stages of the catalytic cycle illustrate the way these pro-
teins recognize and bind DNA, and also the changes that
occur in both substrate and enzyme as they interact with
each other. The details of the atomic mechanism of type
IB enzymes are also well understood. In particular, the
mechanism of cleavage and religation is now very well
dissected by a combination of structural and functional
studies. Finally, type IC topoisomerases, the newest
family of type I enzymes, are not as well understood as
only a few structures are available and the biochemical
work is not as advanced. Nevertheless, the available infor-
mation indicates that type IC enzymes evolved a comple-
tely diﬀerent way of performing essentially the same
reaction. Overall, the structural work on type I enzymes
is now maturing and reaching the stage where many
Figure 6. Structure of a type IC topoisomerase. (A) Diagram showing the structure of a 61kDa fragment of M. kandleri topoisomerase V [PDB
2CSB (72)]. The fragment comprises the topoisomerase domain and four (HhH)2 domains, which are likely to be involved in DNA binding. The
topoisomerase domain, shown in red, and the (HhH)2 domains, shown in tones of blue, are joined by a linker helix, shown in orange. The active site,
shown as ball and stick representation, is buried at the interface of the topoisomerase domain and one of the (HhH)2 domains. To access the active
site, the protein has to change conformation, probably by separating the sub-domains. (B) The putative amino acids forming the topoisomerase V
active site are shown. Aside from the tyrosine, two arginines, a lysine, a histidine and a glutamate form the putative active site. Mutagenesis studies
show that removal of the arginines has a marked detrimental eﬀect on activity. Removal of the glutamate also changes the activity, although not as
markedly. Removal of the histidine and lysine has a modest eﬀect on activity (72).
Nucleic AcidsResearch, 2009, Vol.37,No. 3 699important questions have been answered, but many more
remain unanswered and need to be addressed if we truly
want to have a complete atomic picture of their
mechanism.
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